Natural history and clinical predictors of clinical progression in benign prostatic hyperplasia

Current Opinion in Urology

Volumn 15, Issue 1, 2005, Pages 35-38

  Yan, Kit Fong ^a,b   Milani, Shirin ^a   Djavan, Bob ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b Urologische Universitatsklinik   (Austria)

Author keywords

Natural history; Predictors; Progression; Risk factors

Indexed keywords

DUTASTERIDE; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

BLADDER NECK STENOSIS; CLINICAL STUDY; CLINICAL TRIAL; DISEASE COURSE; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; PREVALENCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; RISK FACTOR; URINARY TRACT INFECTION; URINE FLOW RATE; URINE INCONTINENCE; URINE RETENTION;

DISEASE PROGRESSION; HUMANS; MALE; PROSTATIC HYPERPLASIA; RISK FACTORS;

EID: 12144280604     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200501000-00009     Document Type: Review

References (25)

1. World Health Organization. World Health Annual of Statistics. Geneva: WHO; 1991.
2. Sarma AV, Jacobsen SJ, Girman, et al. Concomitant longitudinal changes in frequency of and bother from lower urinary tract symptoms in community dwelling men. J Urol 2002; 168:1446-1452.
3. Temml C, Brossner C, Schatzl G, et al. The natural history of lower urinary tract symptoms over 5 years. Eur Urol 2003; 43:274-380.
4. Djavan B, Fong YK, Reissigl A, et al. A longitudinal study of men with mild symptoms of bladder outlet obstruction (boo) treated with watchful waiting over 4 years. Urology (in press).
5. Lee AJ, Garraway WM, Simpson RJ, et al. The natural history of untreated LUTS in middle aged and elderly men over a period of 5 years. Eur Urol 1998; 34:325-332.
6. Rhodes T, Girman CJ, Jacobsen SJ, et al. Longitudinal growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol 1999; 16:1174-1179.
7. Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60:434-441.
8. Corica FA, Jacobsen SJ, King BF, et al. Prostatic central zone volume, lower urinary tract symptom severity and peak urinary flow rates in community-dwelling men. J Urol 1999; 161:831-834.
9. Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158:481-487.
10. Meigs JB, Barry MJ, Giovannucci E, et al. Incidence rates and risk factors for acute urinary retention: the health professionals follow up study. J Urol 1999; 162:376-382.
11. McConnell JD, Roehrborn CG, Baustita OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349:2387-2398. A large placebo-controlled, randomized study that analyzes the impact of different medications on clinical progression.
12. Roberts RO, Jacobsen SJ, Jacobson DJ, et al. Longitudinal changes in peak urinary flow rates in a community based cohort. J Urol 2000; 163:107-113.
13. Roehrborn CG, Boyle P, Gould AL, et al. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999; 53:581-589.
14. Roehrbohn CG, McConnell JD, Bonilla J, et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia: PLESS study. J Urol 2000; 163:13-20.
15. Wright EJ, Fang JY, Metter EJ, et al. Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore longitudinal study of aging. J Urol 2002; 167:2484-2488.
16. Roehrborn CG, Boyle P, Bergner D, et al. Serum prostate specific antigen and prostate volume predict long term changes in symptoms and flow rate: results of a four year randomized trial comparing finasteride versus placebo. Urology 1999; 54:662-669.
17. Roehrborn CG, McConnell JD, Leber M, et al. Serum prostate specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology 1999; 53:473-481.
18. McConnell JD. The long-term effects of medical therapy on the progression of BPH: results from the MTOPS trial. J Urol 2002; 167 (Suppl):265, A1042.
19. Roehrborn CG, Malice PP, Cook TK, et al. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 2001; 58:210-216.
20. Roehrbohn CG, Girman CJ, Rhodes T, et al. Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound. Urology 1997; 49:548-557.
21. Roehrbohn CG. Accurate determination of prostate size via digital rectal examination and transrectal ultrasound. Urology 1998; 51 (Suppl 4A):19-22.
22. Mochtar CA, Kiemeney LALM, Van Riemsdijk MM, et al. Prostate specific antigen as an estimator of prostate volume in management of patients with symptomatic benign prostatic hyperplasia. Eur Urol 2003; 44:695-700.
23. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003; 170:530-547.
24. McConnell JD, Bruskewit R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Eng J Med 1998; 338:557-563.
25. Djavan B, Seitz C, Dobrovits M, et al. Multicenter European prospective comparative study of phytotherapy and watchful waiting in men with mild symptoms of bladder outlet obstruction: can progression be delayed or prevented? J Urol 2004; 171:244, A920. This is the first review to assess the efficacy of phytotherapy in men with mild symptoms of bladder outlet obstruction.